ADPT

Adaptive Biotechnologies Corp (ADPT) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through two primary business areas: Minimal Residual Disease (MRD), led by the clonoSEQ diagnostic test, and Immune Medicine, focused on T-cell receptor (TCR) sequencing and target discovery. In June 2026, the company announced an intention to separate these two businesses by year-end 2026 and decided to wind down its research-use-only pharma services (Adaptive Immunosequencing) to focus on target discovery.

Key Financial Metrics

Segment Performance (Q2 2026): MRD revenue was $66.2 million (up 33% YoY), while Immune Medicine revenue was $5.4 million (down 40% YoY). MRD Adjusted EBITDA was positive at $9.1 million, whereas Immune Medicine Adjusted EBITDA was negative at $(6.3) million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 22% in Q2 and 28% YTD, driven primarily by a 43% increase in clonoSEQ test volume (36,111 tests in Q2 2026 vs. 25,321 in Q2 2025).
• Debt Restructuring: In June 2026, the company issued $345.0 million in 0% Convertible Senior Notes due 2031. Proceeds were used to extinguish the existing Revenue Interest Liability (Purchase Agreement) with OrbiMed, resulting in a one-time loss on extinguishment of $23.7 million.
• Share Repurchase: The company repurchased 1,451,800 shares of common stock for $25.0 million in June 2026.
• Expense Management: Research and Development expenses decreased 21% in Q2 and 12% YTD due to reduced investments in drug discovery and clonoSEQ efforts. However, General and Administrative expenses increased 19% in Q2 due to higher legal and billing service fees.
• Collaboration Termination: Immune Medicine revenue declined due to the termination of the Genentech collaboration agreement, which was effective February 9, 2026.

Guidance, Outlook, and Risks

• Strategic Separation: Management intends to separate the Immune Medicine and MRD businesses by the end of 2026 to better realize the long-term potential of the Immune Medicine assets.
• Liquidity: As of June 30, 2026, the company held $371.7 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
• Revenue Outlook: MRD revenue is expected to grow in the short and long term. Immune Medicine revenue is expected to decrease in the short term as Adaptive Immunosequencing services are wound down, with future revenue dependent on target discovery milestones.
• Risks: Key risks include the ability to successfully separate the businesses, the impact of the new convertible notes on future cash flow and potential dilution, and the uncertainty of regulatory milestone payments from biopharmaceutical partners.

Investor Verification Checklist

• Debt Terms: Verify the conversion price ($24.11/share) and redemption terms of the new $345 million Convertible Senior Notes.
• Separation Plan: Monitor progress on the planned separation of the Immune Medicine and MRD businesses by year-end 2026.
• Revenue Quality: Assess the sustainability of MRD revenue growth given the one-time impact of Medicare reimbursement adjustments and the loss of Genentech collaboration revenue.
• Cash Burn: Review the trajectory of operating cash flow, noting the improvement from $(40.9) million to $(15.9) million YTD, and the impact of the $23.7 million non-cash extinguishment loss on GAAP net loss.
• Share Count: Confirm the impact of the recent $25 million share repurchase and potential future dilution from the convertible notes and equity incentive plans.